

CASE STUDY

leadXpro – CASE STUDY

We are committed to create new treatment options for life threatening diseases.

Problem – Challenge

The discovery and development of new drug molecules for treatment of diseases such as cancer or antibiotics that can be used for resistant bacteria is very challenging. Integral membrane proteins are responsible for key signaling and metabolic mechanisms in humans and are excellent drug targets. Drug discovery for new medicines on many membrane protein targets (e.g. GPCR's, ion-channels and transporters) has been limited due to the lack of structural information as well as application of biophysical methods to investigate drug target protein and ligand interaction.

Solution

leadXpro will unlock promising, but challenging membrane protein drug targets and enable the discovery of novel medicines. We are committed to the application of biophysical and structure based methods for the discovery and optimization of next generation lead compounds. We capitalize on expert knowledge of the leadXpro team and the co-localization with the Paul Scherrer Institute (PSI) regarding the experience on membrane protein structural biology, the professional use of facilities like synchrotron (Swiss Light Source) and, in future, the free-electron laser (SwissFEL). Founded in December 2015 and located at the PARK innovAARE, Villigen, Aargau, leadXpro has started lab operations to create a pipeline of own projects and projects in collaborations with pharmaceutical companies.

leadXpro

